Exhibit 10.1
ASSIGNMENT AGREEMENT
This ASSIGNMENT AGREEMENT (this “Agreement”) is effective as of December 28, 2021 (the “Effective Date”), by and among Soleno Therapeutics, Inc., a Delaware corporation, f/k/a Capnia, Inc. (the “Company”), and Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. (collectively, “Vivo”).
Background
A. Reference is made to the Agreement and Plan of Merger and Reorganization, dated as of December 22, 2016, by and among Soleno Therapeutics, Inc., a Delaware corporation, Essentialis, Inc., a Delaware corporation, Company E Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Soleno Therapeutics, and Neil Cowen as the stockholders’ representative (the “Merger Agreement”). Capitalized terms used herein, but not defined, have the meanings ascribed to them in the Merger Agreement.
B. Pursuant to the Merger Agreement, Vivo, as a former stockholder in Essentialis, Inc., has the right to certain Commercial Milestone Cash Payments in the event that the Company achieves certain Commercial Milestones (the “Milestone Payments”).
C. Given the uncertainty as to when or if Vivo will receive the Milestone Payments, how much the Milestone Payments will be payable to Vivo if any, and the urgency of getting Vivo dissolved by the end of 2021, The general partner of Vivo believes that it is in the best interest of Vivo to assign any and all rights to such Milestone Payments to the Company in exchange for the payment by the Company of one U.S. dollar (USD$1.00) to each of Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. (the “Consideration”).
Operative Terms
The Company and Vivo agree as follows:
1. Assignment and Consideration. In exchange for the Consideration, Vivo hereby transfers and assigns to the Company all right, title and interest in and to the Milestone Payments, including any and all interest, fees, income, payments and other proceeds now or hereafter due or payment with respect to the Milestone Payments, and all claims and cause of action for damages, with the right to sue for and collect the same for its own use and on behalf of its successors, affiliates, assigns and other legal representatives, and any notification rights related thereto. Vivo acknowledges and agrees that the Consideration represents fair consideration and at least sufficient value for the assignment of such rights hereunder.
2. Representations and Warranties of Vivo. Vivo represents and warrants to the Company, as of the date of this Agreement, as follows:
(a) Authority. Vivo has the full right, power and authority to enter into this Agreement and to assume and perform its obligations under this Agreement. Vivo has taken all action necessary to authorize its execution and delivery of this Agreement and the performance of its obligations hereunder. Vivo has duly executed and delivered this Agreement, and this Agreement constitutes a valid and legally binding obligation of Vivo, enforceable against Vivo in accordance with its terms.
(b) No Conflict. The execution, delivery and performance of this Agreement by Vivo does not and will not: (i) violate any provisions of law or any order of any court or any governmental entity